FINWIRES · TerminalLIVE
FINWIRES

Illumina, Data-Driven Discovery in Biomedicine Collaborate to Advance Pediatric Cancer, Rare Disease Research

-- Illumina (ILMN) and the Center for Data-Driven Discovery in Biomedicine said Tuesday they have launched a data partnership to advance research in pediatric cancer and rare diseases.

Under the initiative, D3b will analyze 100,000 whole genomes from pediatric patients using Illumina software to build a unified genomic dataset.

The data will be made available through the Gabriella Miller Kids First Data Resource Center to support research and clinical insights, the companies said.

The dataset will include genomes from patients with rare congenital conditions and cancers collected through federally funded programs, including the Children's Brain Tumor Network.

Illumina is also joining the Pediatric Care eXpansion program of the Advanced Research Projects Agency for Health, aimed at accelerating diagnosis and treatment by expanding data-sharing across more than 200 pediatric institutions in the US, according to a joint statement.

Price: $129.43, Change: $+2.47, Percent Change: +1.95%

Related Articles

Asia

Beijing Enlight Media Q1 Profit Falls 99%; Shares Down 8%

Beijing Enlight Media Co (SHE:300251) posted first-quarter attributable net profit of 23.3 million yuan, down 99% from 2.02 billion yuan the previous year.Earnings per share went down to 0.01 yuan from 0.69 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue fell 94% year over year to 190.6 million yuan from 2.97 billion yuan.Shares of the media company were down 8% in recent trade.

$SHE:300251
Asia

Enlight Media 2025 Profit Jumps 473%; Shares Fall 7%

Beijing Enlight Media (SHE:300251) posted 2025 attributable net profit of 1.67 billion yuan, up 473% from 292.0 million yuan the previous year.Earnings per share went up to 0.57 yuan from 0.10 yuan, according to a Wednesday filing with the Shenzhen bourse.Operating revenue jumped 155% year over year to 4.04 billion yuan from 1.59 billion yuan.Shares of the media company were down 7% in recent trade.

$SHE:300251
Asia

CR Double-Crane Pharma Gets Nod to Name Unit as Marketer of Endometriosis Drug

China Resources Double-Crane Pharmaceutical (SHA:600062) received approval from the National Medical Products Administration to change the marketing authorization holder of dienogest tablets, according to a Shanghai bourse filing on Wednesday.Under the approved supplementary application, the pharmaceutical company's subsidiary, CR Zizhu Pharmaceutical, becomes the marketing authorization holder, as well as the manufacturer of the endometriosis drug.

$SHA:600062